Journal
JOURNAL OF MATERIALS CHEMISTRY B
Volume 4, Issue 1, Pages 32-36Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c5tb02123e
Keywords
-
Categories
Funding
- NIH [R01CA161953, T32CA138312, S10OD016240]
Ask authors/readers for more resources
Many small-molecule anti-cancer drugs have short blood half-lives and toxicity issues due to non-specificity. Nanotechnology has shown great promise in addressing these issues. Here, we report the development of anti-cancer drug gemcitabine-conjugated iron oxide nanoparticles for glioblastoma therapy. A glioblastoma targeting peptide, chlorotoxin, was attached after drug conjugation. The nanoparticles have a small size (similar to 32 nm) and uniform size distribution (PDI approximate to 0.1), and are stable in biological medium. The nanoparticles effectively enter cancer cells without losing potency compared to the free drug. Significantly, the nanoparticles showed a prolonged blood half-life and the ability to cross the blood-brain barrier in wild type mice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available